Q3 Earnings Forecast for CNXU Issued By HC Wainwright

Conexeu Sciences Inc. (NASDAQ:CNXU) – Stock analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Conexeu Sciences in a research report issued to clients and investors on Monday, June 22nd. HC Wainwright analyst S. Ramakanth forecasts that the company will earn ($0.10) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. HC Wainwright also issued estimates for Conexeu Sciences’ Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.40) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.15) EPS, FY2027 earnings at ($0.53) EPS, FY2028 earnings at $1.02 EPS, FY2029 earnings at $1.70 EPS and FY2030 earnings at $2.52 EPS.

Separately, Wall Street Zen raised shares of Conexeu Sciences to a “hold” rating in a research note on Saturday, May 30th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $20.00.

Conexeu Sciences Price Performance

CNXU stock opened at $10.24 on Tuesday. Conexeu Sciences has a fifty-two week low of $9.60 and a fifty-two week high of $18.79.

Insider Activity at Conexeu Sciences

In other Conexeu Sciences news, Director Lynn Sebastian Purcell bought 202,500 shares of Conexeu Sciences stock in a transaction on Thursday, June 18th. The stock was acquired at an average price of $0.80 per share, with a total value of $162,000.00. Following the acquisition, the director owned 2,734,240 shares in the company, valued at approximately $2,187,392. This trade represents a 8.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Key Conexeu Sciences News

Here are the key news stories impacting Conexeu Sciences this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Conexeu Sciences and reaffirmed a $20 price target, signaling bullish expectations for the shares. Conexeu Sciences stock page
• Neutral Sentiment: The firm’s updated estimates still point to losses in the near term, including FY2026 EPS of $(0.40) and FY2027 EPS of $(0.53), which suggests investors should expect continued spending before profitability. Conexeu Sciences stock page
• Positive Sentiment: HC Wainwright’s longer-range forecasts turn sharply better, with EPS projected to improve to $1.02 in FY2028, $1.70 in FY2029, and $2.52 in FY2030, implying a meaningful growth trajectory if execution improves. Conexeu Sciences stock page
• Neutral Sentiment: The new quarterly estimates for Q3 2026 through Q4 2027 remain negative, but the sequence shows gradual improvement over time, which may help support investor sentiment. Conexeu Sciences stock page

Conexeu Sciences Company Profile

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.